bioengineering

News

CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.